We hypothesised that anti-EGFR treatment is most effective when added to an oxaliplatin backbone in patients with CMS2/3 tumours in the COIN trial, while patients with mesenchymal CMS4 benefit most from anti-EGFR added to an irinotecan backbone as given in the PICCOLO trial. This evidence concerns the gene EGFR and neoplasm.